Please login to the form below

Not currently logged in
Email:
Password:

FDA warning for BMS’ leukaemia drug

The US Food and Drug Administration has updated the label of Bristol-Myers Squibb's leukaemia drug Sprycel with a warning that the drug can increase the risk of abnormally high blood pressure in the arteries of the lungs

The US Food and Drug Administration (FDA) has updated the label of Bristol-Myers Squibb's (BMS) leukaemia drug Sprycel (dasatinib) with a warning that the drug can increase the risk of abnormally high blood pressure in the arteries of the lungs.

The condition, known as pulmonary arterial hypertension (PAH) is a potentially serious disorder that can weaken the heart and cause shortness of breath, fatigue, and swelling of the body.

The FDA made the updates to Sprycel's label based on data contained in BMS' global pharmacovigilance database that some patients developed PAH after starting Sprycel, including after more than one year of treatment.

Sprycel was initially approved in the US in June 2006. No fatalities from the condition have been reported, according to the FDA.

The regulatory agency also stated that patients diagnosed with PAH during Sprycel therapy were often taking other medications at the same time, and there may be a combination of factors contributing to the development of PAH in patients taking Sprycel.

Healthcare professionals are advised to evaluate patients for signs and symptoms of underlying cardiopulmonary disease prior to starting Sprycel and also during treatment. If PAH is confirmed, Sprycel should be permanently discontinued.

12th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics